Articles related to BREAST CANCER

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.

A randomized phase II trial in 240 premenopausal women evaluated whether low-dose (Z)-endoxifen could reduce mammographic breast density with improved tolerability compared with standard tamoxifen prevention regimens.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

ACP updated guidance recommends shared decision-making rather than routine biennial mammography for average-risk women aged 40 to 49, diverging from the USPSTF recommendation.

Breast cancer screening remains a persistent area of variation in clinical practice. Updated guidance from the American College of Physicians aims to clarify when screening offers meaningful benefit for average‑risk patients — and when it may not.